Real-world outcomes of abiraterone and enzalutamide in first-line treatment of metastatic castration-resistant prostate cancer: which patients benefit most?
MGT Cabetas, M Escario-Gómez… - European Journal of …, 2023 - ejhp.bmj.com
Objectives Abiraterone and enzalutamide are two oral novel androgen receptor axis-
targeted agents approved for the treatment of castration-resistant prostate cancer (mCRPC) …
targeted agents approved for the treatment of castration-resistant prostate cancer (mCRPC) …
Pharmacoeconomic Aspects in Hemophilia
JA Romero-Garrido, M Ayllón-Morales… - Advances in Hemophilia …, 2022 - Springer
Healthcare systems in different countries have the need to cope with an ever-increasing
healthcare demand with increasingly limited resources. The pharmacoeconomic analysis of …
healthcare demand with increasingly limited resources. The pharmacoeconomic analysis of …
[PDF][PDF] TRABAJO FIN DE GRADO Respuesta inmune en esclerosis múltiple
ME Gómez - 2018 - 147.96.70.122
La comprensión de la base inmunopatológica de la Esclerosis Múltiple (EM), una
enfermedad desmielinizante de carácter autoinmune, se ha convertido en un auténtico reto …
enfermedad desmielinizante de carácter autoinmune, se ha convertido en un auténtico reto …